D008862AnatomyA11.284.835.540.541220.999802Microsomes, LiverFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonPediatricsRobertKimuraRobert Kimura349368Kimura, RobertAssistant Professor6Assistant Professor4Professor19797607Zhang X, Galinsky RE, Kimura RE, Quinney SK, Jones DR, Hall SDDrug metabolism and disposition: the biological fate of chemicalsInhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. Drug Metab Dispos. 2010 Jan; 38(1):61-72.Drug Metab Dispos2010-01-01T00:00:002010Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.0.02329290.01628182research area of0.1101490.06513994subject area forNeurological SciencesRush University, Rush Medical Collegetrue1ProfessorProfessorDonnaBergenDonna C. Bergen349839Bergen, DonnaProfessor15519127Ragueneau-Majlessi I, Levy RH, Bergen D, Garnett W, Rosenfeld W, Mather G, Shah J, Grundy JSEpilepsy researchCarbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov; 62(1):1-11.Epilepsy Res2004-11-01T00:00:002004Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.true1Assistant ProfessorAssistant Professor22533986Ashwell MA, Lapierre JM, Brassard C, Bresciano K, Bull C, Cornell-Kennon S, Eathiraj S, France DS, Hall T, Hill J, Kelleher E, Khanapurkar S, Kizer D, Koerner S, Link J, Liu Y, Makhija S, Moussa M, Namdev N, Nguyen K, Nicewonger R, Palma R, Szwaya J, Tandon M, Uppalapati U, Vensel D, Volak LP, Volckova E, Westlund N, Wu H, Yang RY, Chan TCJournal of medicinal chemistryDiscovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J Med Chem. 2012 Jun 14; 55(11):5291-310.J Med Chem2012-05-31T00:00:002012Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.18424157Yang RY, Kizer D, Wu H, Volckova E, Miao XS, Ali SM, Tandon M, Savage RE, Chan TC, Ashwell MABioorganic & medicinal chemistrySynthetic methods for the preparation of ARQ 501 (beta-Lapachone) human blood metabolites. Bioorg Med Chem. 2008 May 15; 16(10):5635-43.Bioorg Med Chem2008-04-01T00:00:002008Synthetic methods for the preparation of ARQ 501 (beta-Lapachone) human blood metabolites.